AI주식인사이트AI Stock Insight
B

코미팜

041960KOSDAQ의약품 제조업

55.8 / 100

Reference Date: 2026-06-10

Financial Score12.5 / 40
News Sentiment21.3 / 25
Momentum12.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Declined 10.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Komipharm is a company established in 1972 specializing in the production and sale of animal vaccines and pharmaceuticals, with key products including ASF vaccines and Pro-vacTM PED-Fc. It is actively expanding globally through the development of cancer treatment drug PAX-1. In 2024, sales increased by 38% year-on-year to 58.8 billion won, with operating profit from animal pharmaceuticals reaching 89.77 billion won.

Number of Employees

172people

Average Salary

47.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 11.934.0Point
PBR
8.54Industry Average 0.890.0Point

9.6x industry avg (risky)

ROE
-11.67Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
12.64Industry Average 12.432.0Point

Higher than industry avg (caution)

Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲13.5% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲65.2% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 0.8% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position6.0Point

52w upper range (62%)

Current 8,330Won52-week high 10,31052-week low 5,060
1-month return1.0Point

1m -10.14% (falling)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral분기보고서 (2026.03)2026-05-14